FDA Approves XFG COVID Vaccines While the Advice Panel Is Frozen

The FDA approved four updated COVID-19 vaccines on Aug. 27, clearing XFG-matched shots for people 65 and older and younger patients at higher risk. Manufacturers said doses would start moving to pharmacies within days.

A March court order still leaves the CDC’s vaccine advisory panel without a quorum, so this season’s payment rules sit with insurers, pharmacies, and state standing orders.

Four Updated Shots Can Leave Factories This Week

The Food and Drug Administration signed off on strain updates from Moderna, Pfizer-BioNTech, and Novavax-Sanofi after the agency’s vaccine advisers backed a monovalent XFG formula in May. Eight of nine members of the Vaccines and Related Biological Products Advisory Committee voted yes, and one abstained. XFG is a JN.1-lineage subvariant that dominated U.S. sequences last season, replacing last year’s LP.8.1 target.

Pfizer and BioNTech said their 2026-2027 formula, COMIRNATY XFG, won a supplemental biologics license for adults 65 and older and for people ages 5 through 64 with at least one underlying condition that raises the chance of severe COVID-19. The companies said shipping will begin immediately to pharmacies, hospitals, and clinics, with product expected in the coming days. Non-clinical data submitted with the file showed immune responses against XFG, XFG.1.1, NB.1.8.1, PQ.17, PQ.2.8.1, and other circulating lineages. Pfizer said more than five billion COMIRNATY doses have been distributed worldwide.

Moderna announced the same day that the agency approved 2026-2027 formulas of Spikevax and mNEXSPIKE containing the JN.1-lineage XFG subvariant. Moderna said Spikevax would be available in the coming days. Novavax and Sanofi said Nuvaxovid, the protein-based option, was cleared on the same narrowed age-and-risk labels used for the other adult products.

Today we announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Applications for the 2026-2027 formulas for Spikevax® (COVID-19 Vaccine, mRNA) and mNEXSPIKE® (COVID-19 Vaccine, mRNA), containing the JN.1-lineage XFG subvariant of… pic.twitter.com/Ydu7Dmef3P

— Moderna (@moderna_tx) August 27, 2026

THE 2026-2027 COVID SHOTS

Those labels are tighter than the universal fall campaigns of earlier years. Healthy children and healthy adults under 65 are outside the licensed groups unless a listed condition applies, and the floor age still depends on which product a clinic stocks.

Who Can Get the XFG COVID Vaccine

Everyone 65 and older is in the approved group for all four shots. Younger people qualify only with at least one condition tied to worse COVID-19 outcomes, and the youngest approved age is 6 months for Moderna’s Spikevax, 5 years for Pfizer-BioNTech, and 12 years for mNEXSPIKE and Nuvaxovid.

CDC materials list a wide set of those conditions, including asthma, heart disease, kidney disease, liver disease, chronic lung disease, diabetes, obesity, and pregnancy. Cancer and a weakened immune system sit on the same list in clinical counseling. That sweep is why a 40-year-old with asthma and a 70-year-old with no other diagnosis can both be offered a shot, while a healthy 30-year-old is not on the label.

CONDITIONS CLINICS SCREEN FOR

• Heart and vessels: Heart disease and related circulatory problems are treated as high-risk for severe COVID-19.
• Lungs and asthma: Asthma and chronic lung disease are listed even when day-to-day symptoms are mild.
• Metabolic disease: Diabetes and obesity are among the most common qualifying diagnoses in adult clinics.
• Kidney and liver: Chronic kidney or liver disease is enough to put a working-age adult on the approved list.
• Pregnancy: Pregnancy is treated as a high-risk condition for severe outcomes.
• Immune status: Cancer care and other immune suppression can qualify a patient and may support extra doses after a clinician visit.

Last fall the CDC moved COVID-19 vaccination to individual-based decision-making, also called shared clinical decision-making, with the note that benefit is highest for people already at elevated risk. That advice still describes the prior season’s formula on some federal pages. It has not been replaced by a fresh 2026-27 vote from the committee that usually writes the immunization schedule.

A March Court Order Left the Advice Panel Empty

The Advisory Committee on Immunization Practices is the group that tells the CDC which shots to recommend, and those recommendations are what most insurers are legally bound to cover at no cost. U.S. District Judge Brian Murphy in Boston stayed the appointments of 13 of 15 sitting members on March 16, 2026, after medical groups led by the American Academy of Pediatrics sued Health Secretary Robert F. Kennedy Jr. Murphy wrote that only six of the 15 members appeared to have meaningful vaccine experience.

ACIP as currently constituted cannot meet, for how can a committee meet without nearly the entirety of its membership?

U.S. District Judge Brian Murphy, March 16, 2026 order

Kennedy had removed all 17 prior members in June 2025 and installed a new slate. The March order also paused votes those members had already taken and blocked a January CDC schedule that cut the number of diseases targeted by routine childhood shots. HHS postponed the panel’s next Atlanta meeting the same week. In April the department posted a renewed charter that widened the specialties that could sit on the committee. On June 18 the Justice Department asked the 1st U.S. Circuit Court of Appeals to lift the bar, arguing the panel lacked a quorum for the annual flu cycle. By late August the freeze was still in place.

HOW THE PANEL WENT DARK

1. June 2025: Kennedy removes all 17 previous ACIP members and names a new roster.
2. September 19, 2025: ACIP shifts COVID-19 vaccination to individual-based decision-making.
3. March 16, 2026: Judge Murphy stays 13 of 15 appointments and the panel’s recent votes.
4. April 2026: HHS publishes a new ACIP charter that broadens listed expertise.
5. May 2026: FDA advisers vote 8-0, with one abstention, to target XFG for 2026-27.
6. June 18, 2026: The Justice Department appeals, saying the panel cannot assemble a quorum.
7. August 27, 2026: FDA approves the XFG shots while ACIP still cannot meet.

Without that committee, CDC has no ordinary path to adopt a 2026-27 COVID recommendation that would automatically bind most private plans. The loud public argument is still about whether COVID shots should be offered at all. The quieter problem is that the body that converts an FDA license into a coverage rule cannot take a seat.

Insurers Pledged Coverage Through 2027

The Affordable Care Act requires most private plans to cover, with no patient cost-sharing, immunizations that have an ACIP recommendation adopted by the CDC director. KFF, which tracks those rules, found that when COVID-19 moved to individual decision-making in 2025 the coverage requirement remains unchanged, because shared clinical decision-making still counts. Medicare Part B covers COVID-19 vaccines by statute, so that program does not wait on ACIP.

AHIP, the trade group whose members cover more than 200 million people, first promised in September 2025 to keep paying for ACIP-recommended shots as they stood on Sept. 1, 2025, including updated COVID-19 and flu formulations, through the end of 2026. A May 2026 update stretched that promise.

Health plans are committed to affordable access to vaccines, and AHIP member health plans will continue covering all ACIP-recommended immunizations with no cost-sharing through the end of 2027.

AHIP, press statement, May 2026 update

That sentence is the floor patients will hear at the counter. It is also pinned to ACIP recommendations. Dr. William Schaffner, an infectious disease specialist at Vanderbilt University and a longtime ACIP adviser, warned in April that newly licensed vaccines and new indications, while legal to prescribe, may not be covered or placed in federal programs if the committee never votes. Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota, put the payer question in one line: “If the vaccine is not fully recommended and it’s a newer vaccine, will the payers pay?” He added, “We don’t have any guarantee of that.”

An insurance-industry source told reporters then that plans would keep reviewing evidence from groups such as the American Academy of Pediatrics and the Infectious Diseases Society of America. Self-insured employer plans, which KFF says cover 67% of people with job-based insurance, sit outside many state coverage mandates. Checking the plan before the visit is still the only hard answer.

Some Pharmacies Will Still Ask for a Prescription

A license is not a standing order. In most states a pharmacist can vaccinate adults under state law or a statewide order. In others, a pharmacist cannot give a shot the CDC has not recommended, which turns a frozen panel into a closed counter. Federal PREP Act authority still lets pharmacy staff administer COVID-19 vaccines through the end of 2029, but states write the day-to-day rules for who may walk in.

Walgreens said on Aug. 28 that it planned to offer the new shots freely to adults in almost all states, with children’s access limited in some places. Pharmacies in Arizona, Oregon, and Utah would still require prescriptions for now. Chain policies can change in a week, and independent stores follow their boards of pharmacy. Calling ahead is the practical step this week, especially for a 12-year-old who qualifies only on one product or a 7-year-old who qualifies only on Spikevax or COMIRNATY.

Inventory will mix for a short stretch as last season’s LP.8.1 doses are used up. Pharmacists have to screen age and conditions at the counter rather than treating COVID-19 like a universal flu walk-in. People who want a non-mRNA option have one licensed choice, Nuvaxovid, and only from age 12. That is a smaller pipeline than the mRNA products, and it takes longer to make.

National Wastewater Levels Stay Very Low

CDC’s respiratory data channel, updated Aug. 28, said the amount of acute respiratory illness sending people to clinics was very low, and that national and regional COVID-19 activity is increasing. Rhinovirus and enterovirus were rising too. That split (quiet clinics, a climbing COVID line) is the usual early-fall pattern, and it is the window in which these shots are meant to land.

WHAT THE CDC DASHBOARDS SHOW

• Wastewater score: The national COVID-19 wastewater viral activity level was 2.14 for the week of Aug. 16 to Aug. 22, inside the very low band that runs up to 2.6.
• Clinic traffic: Acute respiratory illness causing people to seek care was very low as of Aug. 28.
• Direction: National and regional COVID-19 activity was increasing on the same update.
• Flu and RSV: Influenza A and RSV wastewater scores sat at 1.00, also very low, in that mid-August week.

CDC also changed its wastewater scoring method on Aug. 14, applying a two-year baseline at each site, which can make a summer rise look smaller. WastewaterSCAN, a separate university network, has been reading the same sewers as an early-warning thermometer. Amanda Bidwell, the program’s scientific manager, said concentrations had been climbing since late June and that August levels were up 106% from July, with California and Texas among the sharpest increases. CDC’s map still rated almost every state very low, with only a few spots at moderate. Both can be true at once: a low absolute level and a fast recent climb.

Medicare Coverage Does Not Wait on the Panel

Dorit Reiss, a vaccine-policy scholar at the University of California College of the Law, San Francisco, said Medicare still has to cover the shots even with ACIP suspended, while private insurers do not have that statutory duty. AHIP’s pledge of no cost-sharing through the end of 2027 is the industry’s attempt to hold a floor anyway. Patients on Medicare Part B can treat coverage as settled. Everyone else should ask the plan whether this year’s XFG formula is billed as an updated COVID-19 vaccine under last year’s recommendation or as a new product waiting on a vote that cannot happen until the panel exists again.

Pfizer listed myocarditis and pericarditis among rare risks after mRNA COVID-19 vaccines, most often in males 12 to 24, usually within a week, and said people should get care for chest pain, shortness of breath, or a pounding heartbeat. Severe allergic reactions are rare and usually show up within minutes to an hour. Those warnings travel with the product insert; they are not the access fight.

Doses can sit in refrigerators this week. The missing piece is a sitting CDC committee that can say who should get one, and which plans must pay, before the climb in COVID-19 activity gets any steeper.

Disclaimer: This article is news reporting and analysis for general information. It is not medical advice and does not tell any reader whether to receive a COVID-19 vaccine. It is not insurance, billing, or legal advice about a health plan’s benefits or a pharmacy’s rules. Talk with a licensed clinician about your own health, and confirm coverage and eligibility with your insurer or pharmacist before you book a shot. Figures, labels, and the status of the CDC advisory panel reflect the sources as of Sept. 2, 2026, and may change.